Sara A M Musaafir

Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.

G. Storm, J. Garcia-Vallejo, Y. van Kooyk, 2015, Journal of controlled release : official journal of the Controlled Release Society.

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

M. Pirmohamed, A. Cambon-Thomsen, Yitian Zhou, 2023, The Lancet.